Snowdon’s Early Successes

July 9, 2007: Snowdon’s success in attracting funding to development its potential drug candidates was featured in an article authored by Thomas Gaudio in NJBIZ magazine.

June 23, 2007: Snowdon was awarded a two-year $500,000 Edison Innovation Award grant from the New Jersey Commission on Science & Technology (NJCST) to develop its lead compounds for the treatment of toxoplasmosis and related serious parasitic infections.

March 22, 2007: Snowdon secured $500,000 in venture capital funding from the Foundation Venture Capital Group LLC (FVCG). It is the venture firm’s first investment.